semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Breast Cancer Biopsy proven invasive ductal carcinoma of the breast Unifocal disease Patient proceeding to mastectomy  Multifocal disease Previous surgery to ipsilateral breast Neoadjuvant chemotherapy Ferromagnetic implants Claustrophobia Cup size DD or greater
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lymphedema Breast Cancer Stage II Early Disease Onset Gender: female Patients operated with lumpectomy or mastectomy, Sentinel node, axillary lymphnode dissection and/or chemotherapy and/or radiotherapy Controls: operated for colon-rectal carcinoma with colectomy and adjuvant chemotherapy Patients 18 years or older No pre-existing clinical or volumetric signs of lymphoedema (CBO guideline: >10% difference with contra-lateral side  Allergy against one of the used materials Patients who have a pacemaker or other inbuilt stimulator Women who are pregnant Patients with renal failure or heart failure Lymphoedema
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Female patient Ability to provide informed consent and have signed an approved consent form that conforms to federal and institutional guidelines Between 18 and 90 years of age Have been diagnosed with invasive adenocarcinoma, or high-grade ductal carcinoma in-situ. If a core or open biopsy is done, it must demonstrate invasive adenocarcinoma. If only a FNA is done, it must be positive and accompanied by a positive clinical breast examination and ultrasound or mammography. The tumor must be operable Clinically negative lymph nodes Must have had a bilateral mammogram within a year of enrollment The interval between the initial cytologic or histologic diagnosis of breast cancer and enrollment must be no more than 60 days ECOG performance status 0-1 Patients in whom the diagnosis of breast cancer has been obtained utilizing fine needle aspiration cytology or core needle biopsy are preferred. However, patients who are diagnosed by open biopsy procedures are eligible Patients with prior excisional biopsy or lumpectomy are eligible for entry  Male patient Ulceration, erythema, infiltration of the skin or underlying chest wall (complete fixation), peau d'orange, or skin edema of any magnitude. (Tethering or dimpling of the skin or nipple inversion should not be interpreted as skin infiltration. Patients with these latter to conditions are eligible.) One or more ipsilateral axillary lymph nodes that are positive for tumor on clinical examination Bilateral malignancy or a mass in the opposite breast that is suspicious for malignancy, unless a biopsy proves that the mass is not malignant Previous removal of any ipsilateral axillary lymph node Diffuse tumors or multiple malignant tumors in different quadrants of the breast Suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes. Patients with these conditions are considered ineligible unless there is biopsy evidence that these are not involved with tumor Patients with any prior breast malignancy other than LCIS Prior treatment for this breast cancer including irradiation, chemotherapy, immunotherapy, and/or hormonal therapy Allergy to radiocolloid or fluorescein
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infiltrating Bladder Urothelial Carcinoma Age ≥18 years Histologically confirmed primary transitional cell carcinoma (TCC) of the urinary bladder T2 to T4 disease, N0 M0 determined by computerised tomography (CT) imaging and biopsy or transurethral resection Eastern Co-operative Oncology Group (ECOG) Performance status 0 or 1 Glomerular filtration rate (GFR) ≥60ml/min Written, informed consent  ECOG Performance Status ≥ 2 Lymph node involvement or metastatic disease Prior surgery (except transurethral resection of bladder tumour), radiation, che-motherapy, or other anti-cancer therapy within 4 weeks prior to enrolment Active Grade ≥2 peripheral neuropathy Active secondary cancers History of severe hypersensitivity reaction (≥Grade 3) to polysorbate 80 containing drugs Other concurrent serious illness or medical conditions Inadequate organ function as evidenced by peripheral blood counts at enrolment Electrocardiogram (ECG) evidence of uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension, history of congestive heart failure, or myocardial infarction within last 6 months Uncontrolled diabetes mellitus
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infiltrating Ductal Carcinoma Invasive non-lobular breast cancer, histologically proven by biopsy Tumour T2 T3 regardless of nodal status, stemming from a primary surgery, in whom FDG-PET is performed for staging Age greater than or equal to 18 years Good condition: WHO lower 2 Women receiving effective contraception throughout the duration of treatment and 3 months after cessation of treatment Patient has signed informed consent  Carcinoma other than breast ductal carcinoma Patients for whom no target tumor is assessable Patients for whom surgery first of their breast cancer is not indicated (tumor spread, metastasis, general health, co-morbidities) Pregnant women, or likely to be during breastfeeding Major protected (under supervision and under guardianship) Failure to submit to medical supervision of the study for reasons of geography, social or psychological Incomplete tumor resection
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infiltrating Duct and Lobular Carcinoma In Situ Invasive Lobular Breast Carcinoma Inflammatory Breast Carcinoma Previously untreated (no chemotherapy, hormonal or radiation therapy)invasive breast cancer Diagnosis of invasive ductal or lobular breast cancer plus or minus DCIS. Inflammatory carcinoma will also be elegible Age≥ 18 years Only female patients are eligible Tumor≥ 1.0cm by MRI and/or sonographic or clinical exam measurements. If the tumor is <1.0 but the patient has biopsy proven lymph node metastasis, she will also be considered eligible.Although only tumors≥2cm are consideredmeasurable by we will nevertheless tumors≥1cm since the primary endpoint is pathological CR rate Performance status ECOG≤2 or Karnofsky≥ 50% Peripheral neuropathy≤ grade 1 Hematologic (minimal values):Absolute Neutrophil count≥1,500/mm³; Hemoglobin≥8.0g/dl; Paltelet count≥100,000/mm³ Hepatic; Total bilirubin≤ULN AST and ALT and ALP do not have to be within the range. In determining the more abnormal of the two values(AST or ALT) should be use as per protocol table on p.24of 69 Women of childbearing potential must have a negative pregnancy test  Pregnant or breast feeding patients are excluded Patients with second malignancies with expected survival<5 years Previous chemotherapy with Taxanes,Anthracyclines or Cyclophosphamide Patientes with history of severe hypersensitivity reaction to Taxotere(Docetaxel)or other drugs formulated with polysorbate 80 Pure DCIS diagnoses are not elegible Special histologies with favorable prognosis such as mucinous, tubular are not elegible Patients with reduced ejection fraction<50% are not eligible Patients with tumors<1.0cm unless biopsy proven axillary node metastasis present Cardiac thrombotic events in the past 12 months Stroke or transient ischemic attacks (TIA) within 12 months
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer Karnofsky ≥ 70 2. Provision of informed consent 3. Pathological confirmation of invasive ductal carcinoma and estrogen receptor is positive 4. Tumor stage(TNM):T2-4bN0-3M0 5. Premenopausal woman 6. Not previously received treatment with bisphosphonate 7. Laboratory PLT ≥ 100*109/L WBC ≥ 4000/mm3 HGB ≥ 10g/dl GOT,GPT,ALP ≤ 2*ULN TBIL,DBIL,CCr ≤ 1.5*ULN  Pregnant or lactation woman 2. History of organ transplantation 3. With mental disease 4. With severe infection or active gastrointestinal ulcers 5. With severe liver disease (such as cirrhosis), kidney disease, respiratory disease or diabetes 6. Disease-free period of other malignant tumor is less than 5 years(except cured basal cell skin cancer and cervical carcinoma in situ) 7. With heart disease 8. Experimental drug allergy
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Breast Cancer Subgroup 1, Patients with breast lesions: -At least one breast lesion detected by mammogram, ultrasound or breast MRI that measures < 20 mm in greatest dimension, presents as a mass, is considered suspicious or highly suggestive of malignancy according to the Breast Imaging Reporting and Data System Atlas (BIRADS 4 or 5), and is scheduled for core-needle biopsy or surgical biopsy. OR -At least one breast lesion that measures between > 10 mm but < 20 mm in greatest dimension, presents as a mass, is biopsy-proven as malignant, and is scheduled for surgical resection. AND Age > 40 years Negative pregnancy test, postmenopausal, or surgically sterilized Subgroup 2, Patients without known breast lesions Negative screening mammogram performed at Mayo Clinic Rochester within 15 months prior to performance of study MBI No signs or symptoms of breast disease Age > 40 years Negative pregnancy test, postmenopausal, or surgically sterilized  Vacuum-assisted or excisional biopsy has been performed prior to the study MBI. Reason: these types of biopsies are more likely to remove all of the tumor MBI is performed after biopsy and neo-adjuvant chemotherapy is planned prior to surgery. Reason: true tumor size will not be able to be ascertained from the final pathology findings Breast implants. Reason: cases with breast implants will be easily identifiable on blinded interpretation to take place at the study end Suspected that breasts will not fit in the MBI field of view. Reason: cases that require tiled views or additional views will be easily identifiable on blinded interpretation to take place at the study end Only one breast remaining. Reason: unilateral cases will be easily identifiable on blinded interpretation to take place at the study end; injection timing is designed for bilateral views Pregnancy test (if necessary) is not negative, or the patient is unable to complete the pregnancy test Physically unable to sit upright and still remain still during two consecutive MBI studies over the course of a 2-hour period
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Hepatocellular Carcinoma hepatocellular patients diagnosed through biopsy;or either dynamic imagine with a diagnosis of hepatocellular carcinoma and alphafetoprotein>400μg/L；or two or more dynamic imagine with a diagnosis of hepatocellular carcinoma Child-Pugh A or B well preserved renal and hematopoietic Function receive ablation therapy through percutaneous radiofrequency ablation or microwave ablation or ethanol injection ablation or any kind of combination of them achieve complete ablation accessed by contrast-enhanced CT  incomplete ablation remote metastasis Child-Pugh C general infection autoimmune diseases suffer from other tumors concurrently or in last five years patients with immune deficit or infected by HIV receiving glucocorticoid or other medicine inhibiting immune system
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Carcinoma Unifocal primary invasive ductal breast carcinoma diagnosed by core needle biopsy. Patients with contralateral disease will remain eligible. Note: Results of ER, PR, HER-2/neu must be obtained on pre-registration needle core biopsy material Tumor size ≤ 2.0 cm in greatest diameter as measured by breast ultrasound, MRI and mammogram. The largest dimension measured will be used to determine eligibility Tumor enhancement on MRI Tumor with <25% intraductal components in the aggregate Non-pregnant and non-lactating patients. Patients of childbearing potential must have a negative serum or urine pregnancy test. NOTE: Peri-menopausal women must be amenorrheic for > 12 months to be considered not of childbearing potential Adequate breast size for safe cryoablation. Patients with breasts too small to allow safe cryoablation are not eligible as the minimal thickness of the breast tissue does not lend itself to cryoablation. NOTE: The minimal distance of tumor margins from the breast skin should be analogous to the surgical margins of a lumpectomy  Patients with multifocal and/or multicentric ipsilateral breast cancer, multifocal calcifications, or evidence of excessive DCIS History of rotational vacuum assisted core biopsies, en bloc open surgical biopsy and/or lumpectomy for diagnosis/treatment of the index breast cancer Prior or planned neoadjuvant chemotherapy for breast cancer Patients with thrombocytopenia and or any other coagulation abnormality
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 4.0-999.0,  Juvenile Idiopathic Arthritis Patients who completed visit 33 (week 104) of WA19977 study and who may benefit from study drug treatment according to the investigator's assessment Patients have to receive the first RoActemra/Actemra infusion in this study at the Week 8 visit at the latest Females of child-bearing potential and males with female partners of child-bearing potential must agree to use effective contraception as defined by protocol  Patients with, according to investigator judgment, not satisfactory benefit from RoActemra/Actemra therapy within WA19977 Treatment with any investigational agent since the last administration of study drug in the core study WA19977 Patient developed any other autoimmune rheumatic disease or overlap syndrome other than the permitted polyarticular-course Juvenile Idiopathic Arthritis (JIA) subsets: rheumatoid factor positive or negative JIA or extended oligoarticular JIA Patient is pregnant , lactating, or intending to become pregnant during the study and up to 12 weeks after the last administration of study drug Any significant concomitant disease or medical or surgical condition History of significant allergic or infusion reactions to prior biologic therapy Currently active primary or secondary immunodeficiency Any infections with contraindications to RoActemra/Actemra therapy according to investigator judgment Inadequate hepatic, renal or bone marrow function